Evidence map›Paper›PMID 40574973›Full record

ArticleBrain communications2025

Mapping CD4+ T cell diversity in CSF to identify endophenotypes of multiple sclerosis.

Tadhg Crowley, Jessy Chen, Kamil S Rosiewicz, Lea Jopp-Saile, Gesche Herold, Charlotte Biese, Cornelius Fischer, Janis Kerkering, Marlen Alisch, Friedemann Paul and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tadhg CrowleyExperimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin and Max Delbrück Center or Molecular Medicine in the Helmholtz Association, Berlin 13125, Germany.
Jessy ChenExperimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin and Max Delbrück Center or Molecular Medicine in the Helmholtz Association, Berlin 13125, Germany.
Kamil S RosiewiczExperimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin and Max Delbrück Center or Molecular Medicine in the Helmholtz Association, Berlin 13125, Germany.
Lea Jopp-SaileFaculty of Biosciences, University of Heidelberg, 69120 Heidelberg, Germany.
Gesche HeroldExperimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin and Max Delbrück Center or Molecular Medicine in the Helmholtz Association, Berlin 13125, Germany.
Charlotte BieseExperimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin and Max Delbrück Center or Molecular Medicine in the Helmholtz Association, Berlin 13125, Germany.
Cornelius FischerBerlin Institute of Health (BIH), Charité Universitätsmedizin Berlin, Berlin 10178, Germany.
Janis KerkeringExperimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin and Max Delbrück Center or Molecular Medicine in the Helmholtz Association, Berlin 13125, Germany.
Marlen AlischExperimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin and Max Delbrück Center or Molecular Medicine in the Helmholtz Association, Berlin 13125, Germany.
Friedemann PaulExperimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin and Max Delbrück Center or Molecular Medicine in the Helmholtz Association, Berlin 13125, Germany.
Volker SiffrinExperimental and Clinical Research Center (ECRC), Charité-Universitätsmedizin Berlin and Max Delbrück Center or Molecular Medicine in the Helmholtz Association, Berlin 13125, Germany.ORCID https://orcid.org/0000-0002-1532-2868

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic inflammatory CNS disease with heterogeneous manifestation. Prognostic markers for early classification of MS are currently under investigation. Higher diagnostic resolution of cerebrospinal fluid (CSF) has the potential to contribute significantly to patient stratification, which should be especially important for a subgroup of patients with high risk to convert to a progressive disease course. This study aimed to determine whether spectral flow cytometry of CSF cells could identify pathogenic CD4+ T cell subset in MS. Using a two-step approach, we designed a marker panel informed by publicly available transcriptomic datasets from early human MS and our own single-cell RNA sequencing (scRNA-seq) in acute and chronic experimental autoimmune encephalomyelitis (EAE), a murine MS model. Notably, chronic ('phase') markers such as

Indexed as

cerebrospinal fluidchronic neuroinflammationexperimental neuroinflammationmultiple sclerosisT cell subsets

Identifiers

PMID40574973
PMCPMC12199765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.